PMAI offers new addiction treatment options for opioid dependence

Punyamurtula S. Kishore MD, MPH, FASAM, of Preventive Medicine Associates, Inc. (PMAI), the largest outpatient substance dependence provider in Massachusetts, announced today his 37 clinical locations will be offering new addiction treatment options through the use of VIVITROL® (naltrexone for extended-release injectable suspension), which was approved on Tuesday, October 12, 2010 by the U.S. Food and Drug Administration (FDA) for the prevention of relapse to opioid dependence.

“This news is a major breakthrough in addiction treatment”

Dr. Kishore and PMAI have been leading the charge with the use of VIVITROL since 2006, when it was first approved for the treatment for alcohol dependence. With new FDA approval, the once-monthly medication is now available for use to treat additional addiction behaviors. According to a press release issued on October 12 by the drug's manufacturer, Alkermes, Inc., VIVITROL is now the first and only non-narcotic, non-addictive, once-monthly medication approved for the treatment of opioid dependence.

"This news is a major breakthrough in addiction treatment," said PMAI Founder and President Punyamurtula S. Kishore. "At Preventative Medicine Associates, Inc. we are dedicated to providing our patients with proven and evidence-based treatment options to help them in their battle against alcohol and drug dependence. The FDA's approval to administer this drug in a larger capacity allows for new addiction treatment options across the board. We were a leader with VIVITROL administration back in 2006, and we look forward to providing our patients even more enhanced treatment options today," he added.

Across their 37 treatment centers in Massachusetts, PMAI treats 12,000 unique patients each year for substance dependencies among its network of addiction medicine providers with 144,000 patient visits per year. For more information about VIVITROL's availability at PMAI locations, please contact Dr. Kishore at 1-800-770-1904 or for full prescribing information, including boxed warning, please visit www.vivitrol.com or call 1-800-VIVITROL.

Source:

Preventive Medicine Associates, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Treating volatile exhaust streams in the pharmaceutical industry: an interview with Jeff Kudronowicz